Skip to main content
  1. Market Insights
  2. Health
  3. Hospitals
  4. Inpatient Care

Gastroenterology - India

India
  • The Gastroenterology market in India is forecasted to achieve a revenue of INR US$5.21bn by the year 2025.
  • It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2025-2029) of 6.91%.
  • As a result, the market volume is expected to reach INR US$6.81bn by 2029.
  • When compared to other countries worldwide, United States is projected to generate the highest revenue in the Gastroenterology market, with an estimated amount of INR US$61.45bn in 2025.
  • India is experiencing a surge in demand for gastrointestinal treatments due to a rise in urbanization and changing dietary habits.

Definition:
Gastroenterology refers to medical treatments and procedures that are provided to patients who require overnight hospitalization for digestive system disorders, e.g., gastrointestinal motility disorders, inflammatory bowel diseases, and liver diseases. Patients are provided with a variety of services during their stay in the hospital. These include endoscopic procedures (e.g., colonoscopies or upper endoscopies), surgical interventions, and changes to their diet and lifestyle that help manage the underlying condition and improve digestive health.

Additional information:
The Gastroenterology market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.

In-Scope
  • Diagnostic and therapeutic endoscopic procedures
  • Surgical interventions for digestive system diseases
  • Monitoring and management of patients receiving nutrition support
Out-Of-Scope
  • Treatment of chronic digestive system diseases that do not require hospitalization
  • Routine follow-up care after hospitals discharge
Hospitals
Hospitals
XMO_RELATED_MARKETS
Inflammatory bowel disease (IBD) in the U.S. - Cover

Statistics report on inflammatory bowel disease (IBD) in the U.S.

Inflammatory bowel disease (IBD) in the U.S.
CONTENTBOX_CAPTION_STUDY_DETAILS
    methodology
    DOWNLOAD_PDF_TEXTXMI_FAQ_AND_ADDITIONAL_INFO

    Revenue

    NOTES: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    MOST_RECENT_UPDATE: Apr 2024

    SOURCE: Statista Market Insights

    MOST_RECENT_UPDATE: Apr 2024

    SOURCE: Statista Market Insights

    Global Comparison

    MOST_RECENT_UPDATE: Apr 2024

    SOURCE: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

    Modeling approach / Market size:

    Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

    Health

    XMO_REPORT_PROMO_HEADLINE

    Inflammatory bowel disease (IBD) in the U.S. - BackgroundInflammatory bowel disease (IBD) in the U.S. - Cover

    Key Market Indicators

    NOTES: Based on data from IMF, World Bank, UN and Eurostat

    MOST_RECENT_UPDATE: Jan 2025

    SOURCE: Statista Market Insights

    OUTLOOK_EXPLORE_RELATED_TOPICS

    Inflammatory bowel disease in the U.S. - Statistics & Facts

    Inflammatory bowel disease (IBD) refers to disorders that cause chronic inflammation of the digestive tract. The two most common types of IBD are Crohn’s disease and ulcerative colitis. IBD can be difficult to diagnose because symptoms are typical of other illnesses and diseases and can vary from person to person. Symptoms of IBD include diarrhea, stomach pain and cramping, bleeding ulcers, weight loss, and fatigue. A survey of patients with Crohn's disease in North America and Europe found that 56 percent had experienced tiredness/exhaustion/fatigue in the past month, while 53 percent had abdominal pain/cramps. Such symptoms were only slightly less common among patients with ulcerative colitis.
    OUTLOOK_MORE_DATA_ON_TOPIC
    Number of adults aged 18 to 24 years with Crohn's disease or ulcerative colitis in the U.S.
    152,000
    U.S. region with the highest percentage of people with Crohn's disease or ulcerative colitis
    Northeast/South
    Most common symptom among IBD patients in the U.S.
    Fatigue

    Contact

    Get in touch with us. We are happy to help.
    Meredith Alda
    Sales Manager
    Email
    support@statista.com
    Tel
    +1 914 619-5895

    Mon - Fri, 9am - 6pm (EST)

    Lodovica Biagi
    Director of Operations
    Email
    eu.support@statista.com
    Tel
    +44 (0)20 8189 7000

    Mon - Fri, 9:30am - 5pm (GMT)

    Ayana Mizuno
    Business Development Manager
    Email
    asia.support@statista.com

    Mon - Fri, 10:00am - 6:00pm (JST)

    Carolina Dulin
    Group Director - LATAM
    Email
    latam@statista.com
    Tel
    +1 212 419-5774

    Mon - Fri, 9am - 6pm (EST)

    Yolanda Mega
    Operations Manager
    Email
    asia.support@statista.com
    Tel
    +65 6995 6959

    Mon - Fri, 9am - 5pm (SGT)